Recommendations for Social Skills End Points for Clinical Trials in Neurofibromatosis Type 1.

Neurology

From the Children's Hospital Colorado and University of Colorado School of Medicine (J.A.J.), Aurora; Department of Psychology (B.P.K.-T.), University of Wisconsin-Milwaukee; Murdoch Children's Research Institute and Department of Pediatrics (J.M.P., K.H.), University of Melbourne, Australia; Pediatric Oncology Branch (P.L.W., S.M., M.A.T.-T.), National Cancer Institute, Bethesda, MD; Department of Communication Sciences and Disorders (H.L.T.), California State University, Sacramento; University of Cincinnati Medical Center (P.d.B.), OH; Boston Children's Hospital (N.U.), MA; Children's National Hospital, Gilbert NF Institute (A.d.C., K.K.H., K.S.W.), Washington, DC; Children's Tumor Foundation (M.H.), New York, NY; The George Washington School of Medicine (K.K.H., K.S.W.), Washington, DC; Children's Hospital Los Angeles (T.R.), CA; and Leidos Biomedical Research, Inc. (M.A.T.-T.), Frederick, MD.

Published: August 2021

AI Article Synopsis

  • The objective of the study was to review social skills measures reported by parents to find suitable options for clinical trials focused on social deficits in children and adolescents (ages 6-18) with neurofibromatosis type 1 (NF1).
  • Research involved searching databases to identify relevant outcome measures used in recent clinical trials involving populations with known social skills challenges, such as ADHD and autism spectrum disorder (ASD), which were then rated for various criteria.
  • The committee recommended two measures: the Social Responsiveness Scale-2 (SRS-2), best for studies on problematic behaviors associated with ASD, and the Social Skills Improvement System-Rating Scale (SSIS-RS), suitable for broader social functioning assessments; recommendations

Article Abstract

Objective: To review parent-report social skills measures to identify and recommend consensus outcomes for use in clinical trials of social deficit in children and adolescents (ages 6-18 years) with neurofibromatosis type 1 (NF1).

Methods: Searches were conducted via PubMed and ClinicalTrials.gov to identity social skills outcome measures with English language versions used in clinical trials in the past 5 years with populations with known social skills deficits, including attention-deficit/hyperactivity disorder and autism spectrum disorder (ASD). Measures were rated by the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) Neurocognitive Committee on patient characteristics, use in published studies, domains assessed, availability of standard scores, psychometric properties, and feasibility to determine their appropriateness for use in NF1 clinical trials.

Results: Two measures were ultimately recommended by the committee: the Social Responsiveness Scale-2 (SRS-2) and the Social Skills Improvement System-Rating Scale (SSIS-RS).

Conclusions: Each of the 2 measures assesses different aspects of social functioning. The SSIS-RS is appropriate for studies focused on broader social functioning; the SRS-2 is best for studies targeting problematic social behaviors associated with ASD. Researchers will need to consider the goals of their study when choosing a measure, and specific recommendations for their use are provided.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594002PMC
http://dx.doi.org/10.1212/WNL.0000000000012422DOI Listing

Publication Analysis

Top Keywords

social skills
20
clinical trials
12
social
9
neurofibromatosis type
8
social functioning
8
skills
5
measures
5
recommendations social
4
skills points
4
clinical
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!